Table 2.
Methylation positive detection rate by the formerly validated three-marker panel (ASCL1, ZNF582, SST) and the newly developed ASCL1/ZNF582 multiplex assay.
| No dysplasia, n (%) |
AIN1, n (%) |
AIN2, n (%) |
AIN3, n (%) |
SCC, n (%) |
|
|---|---|---|---|---|---|
| hrHPV testing | 2/23 (8.7) |
d4/16 (25.0) |
19/25 (76.0) |
28/31 (90.3) |
15/15 (100.0) |
| aThree-marker panel (ASCL1, ZNF582, SST) | 8/23 (34.8) |
5/17 (29.4) |
10/25 (40.0) |
20/31 (64.5) |
14/15 (93.3) |
| bASCL1/ZNF582 multiplex assay: 70% specificity | 8/23 (34.8) |
4/17 (23.5) |
9/25 (36.0) |
18/31 (58.1) |
15/15 (100.0) |
| cASCL1/ZNF582 multiplex assay: 80% specificity | 4/23 (17.4) |
4/17 (23.5) |
7/25 (28.0) |
16/31 (51.6) |
15/15 (100.0) |
a
Threshold was set as defined by van der Zee et al. [3].
b
Threshold was set corresponding to a predefined specificity of 80% with cases defined as AIN3 and controls as ≤AIN1.
c
Threshold was set corresponding to a predefined specificity of 70% with cases defined as AIN3 and controls as ≤AIN1.
d
For 1 of the AIN1 biopsies no hrHPV testing was performed.